$ABBV (AbbVie Inc.)

$ABBV {{ '2015-11-30T18:01:15+0000' | timeago}} • SEC

For remainder of 2015, $ABBV expects to achieve operating margin improvements while continuing to invest in its pipeline in support of opportunities in oncology, HCV, and immunology, as well as investment in key products. $ABBV expects to grow operating cash flows in 2015.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$ABBV {{ '2017-06-23T16:10:50+0000' | timeago}} • Announcement

$ABBV said Maviret, if approved, will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes (GT1-6), who comprise the majority of people living with HCV. The European Commission will now review the CHMP opinion and a final decision is expected in 3Q17.

$ABBV {{ '2017-06-23T16:10:05+0000' | timeago}} • Announcement

$ABBV said the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending marketing authorization of Maviret, an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection.

$ABBV {{ '2017-06-23T11:59:17+0000' | timeago}} • Announcement

Pharma company $ABBV said the pivotal phase-2 study on its leukaemia drug Venlcyxto, a first-in-class oral B-cell lymphoma-2 inhibitor, yielded encouraging results. The results will be presented at the European Hematology Association meeting. The study was conducted on patients with CLL and 17p deletion who were refractory to prior treatments.

$ABBV {{ '2017-06-23T10:44:35+0000' | timeago}} • Announcement

$ABBV's BoD declared  a quarterly cash dividend of $0.64 per share. The dividend is payable on Aug. 15, 2017, to stockholders of record at the close of business on July 14, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$ABBV {{ '2017-06-13T14:49:59+0000' | timeago}} • Announcement

$ABBV and Principia Biopharma entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.

$ABBV {{ '2017-06-12T11:26:02+0000' | timeago}} • Announcement

$ABBV will present data from multiple clinical trials evaluating its leukaemia drug venetoclax at the 22nd European Hematology Association Annual Congress to be held in Madrid. Data will be presented from 15 studies across common hematologic malignancies, including chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

$ABBV {{ '2017-05-15T10:56:24+0000' | timeago}} • Announcement

$ABBV announced results from an analysis of data pooled from three Phase 3 studies evaluating Imbruvica (ibrutinib) use in patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). CLL is a type of cancer that starts from cells that become certain white blood cells in the bone marrow.

$ABBV {{ '2017-04-27T15:14:17+0000' | timeago}} • Infographic

$ABBV AbbVie Inc. Earnings AlphaGraphics: Q1 2017 highlights

$ABBV {{ '2017-04-27T14:58:13+0000' | timeago}} • Webcast

On share buyback in 1Q17, $ABBV stated that it bought back $500MM of shares. However, the company added that it is not the company's intent currently to buyback significantly more shares. $ABBV also said that to the extent it finds itself with an excess of US cash, it does deploy that in the market from time to time and buyback shares.

$ABBV {{ '2017-04-27T14:48:55+0000' | timeago}} • Webcast

$ABBV said that cash on hand at the end of FY16 was $8.2Bil. And in terms of geographic distribution of cash, under the current tax rules there is a penalty for bringing back cash back into the US. Therefore, $ABBV is bringing back cash that is only needed to cover its US cash needs like interest and dividends.

$ABBV {{ '2017-04-27T14:13:11+0000' | timeago}} • Webcast

$ABBV commented that in terms of debt, it is not the company's intent to significantly pay down debt in the current environment. On bolt on acquisitions, $ABBV added that it is focused on the strategic road-map on how it is trying to operate within the franchises as there is no need for large platforms.

$ABBV {{ '2017-04-27T12:28:02+0000' | timeago}} • Announcement

$ABBV is confirming its diluted EPS guidance for full-year 2017 of $4.55-4.65. $ABBV expects adjusted diluted EPS of $5.44-5.54, representing growth of 13.9% at the mid-point. The company's 2017 adjusted diluted EPS guidance excludes $0.89 per share of intangible asset amortization expense and other items.

$ABBV {{ '2017-04-27T12:25:23+0000' | timeago}} • Announcement

$ABBV reported an increase in 1Q17 earnings. Net income was $1.71Bil or $1.06 per share compared to $1.35Bil or $0.83 per share in 1Q16. Adjusted diluted EPS was $1.28, up 11.3%. Worldwide net revenues were $6.53Bil, increasing 10.1%, excluding a 0.4% unfavorable impact from FX.

$ABBV {{ '2017-04-21T13:03:52+0000' | timeago}} • Announcement

$ABBV said eight weeks of treatment with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir achieved high SVR rates in challenging to treat genotype 3 chronic hepatitis C.

$ENTA {{ '2017-04-20T15:33:39+0000' | timeago}} • Announcement

$ENTA said 99% SVR12 rate in chronic hepatitis C virus (HCV) patients with compensated cirrhosis treated with $ABBV's investigational, pan-genotypic, ribavirin free regimen of glecaprevir/pibrentasvir.

$ABBV {{ '2017-03-30T13:04:53+0000' | timeago}} • Announcement

$ABBV said the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis.

$ENTA {{ '2017-03-14T17:47:32+0000' | timeago}} • Announcement

$ENTA announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare to $ABBV for its investigational, pan-genotypic, ribavirin-free combination of glecaprevir/pibrentasvir (G/P) for the treatment of all major genotypes (GT1-6) of chronic hepatitis C virus infection.

$ABBV {{ '2017-02-27T13:30:17+0000' | timeago}} • Announcement

$ABBV said the European Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for a shorter, 8-week treatment of Viekirax  Exviera as an option for previously untreated adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and minimal to moderate fibrosis.

Recent Transcripts

MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
NKTR (Nektar Therapeutics)
Tuesday, May 9 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, April 27 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
NKTR (Nektar Therapeutics)
Wednesday, March 1 2017 - 10:00pm

AlphaGraphics you may like